Gerard J. Platenburg
Founder chez PROQR THERAPEUTICS N.V.
Provenance du réseau au premier degré de Gerard J. Platenburg
| Entité | Type d'entité | Industrie | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 30 | |
University of Leiden
22
| College/University | Other Consumer Services | 22 |
| Extinct | Biotechnology | 14 | |
ISA Pharmaceuticals BV
 ISA Pharmaceuticals BV Pharmaceuticals: MajorHealth Technology ISA Pharmaceuticals BV operates as a clinical-stage immunotherapy company. The firm develops novel therapeutic vaccines for cancer and infectious diseases. Its product portfolio builds on its proprietary SLP-technology (Synthetic Long Peptide) for the development of therapeutic vaccines. The firm holds the exclusive rights to LUMC's patent families for amongst others, the development of therapeutic vaccines. The company was founded by Cornelis J. M. Melief in 2004 and is headquartered in Leiden, the Netherlands.
1
| Holding Company | Pharmaceuticals: Major | 1 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Gerard J. Platenburg via son réseau personnel
| Société | Secteur | Personnes liées | Poste principal |
|---|---|---|---|
| GILEAD SCIENCES, INC. | Biotechnology | Corporate Officer/Principal Treasurer | |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Medical Specialties | Chief Executive Officer Corporate Officer/Principal Sales & Marketing | |
| GALAPAGOS NV | Biotechnology | Director/Board Member President | |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
| Nyenrode Business Universiteit | College/University | Undergraduate Degree Director/Board Member | |
| AURA BIOSCIENCES, INC. | Biotechnology | Director/Board Member Chief Operating Officer | |
| GSK PLC | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
| MORPHOSYS AG | Biotechnology | Corporate Officer/Principal Corporate Officer/Principal | |
LSP Management Group BV
 LSP Management Group BV Investment ManagersFinance LSP Management Group BV (LSP) is an independent European venture capital firm which was founded by Martijn Kleijwegt, Frits van der Have and Tom Schwarz in 1998. Headquartered in Amsterdam, the firm provides financing to early- to mid-stage life science companies. | Investment Managers | Founder Private Equity Investor Private Equity Investor | |
Abingworth LLP
 Abingworth LLP Investment ManagersFinance Abingworth LLP is a venture capital firm founded in the year 1973 Peter Dickson and Anthony Montagu. The firm headquartered in London and additional offices in San Francisco and Boston. | Investment Managers | Consultant / Advisor Private Equity Investor | |
Galapagos Biotech Ltd.
 Galapagos Biotech Ltd. BiotechnologyHealth Technology Galapagos Biotech Ltd. operates as a drug discovery company which provides discovery technologies and services. Its technologies include Chemogenomics and Silico. The company was founded by Kenneth Leslie Powell and Janet Maureen Thornton in July 8, 1997 and is headquartered in Cambridge, the United Kingdom. | Biotechnology | Director/Board Member Director/Board Member | |
| The University of Texas at Austin | College/University | Doctorate Degree Doctorate Degree | |
| INSEAD | College/University | Masters Business Admin Masters Business Admin | |
| University of Bristol | College/University | Doctorate Degree Doctorate Degree | |
CropDesign NV
 CropDesign NV Miscellaneous Commercial ServicesCommercial Services CropDesign NV develops traits for cereal crops. It delivers agronomic traits for the global commercial seed markets. The firm focuses on enhancing grain yield in crops such as corn and rice, and increasing biomass of energy crops. Its platform, TraitMill, lows evaluating the effect of genes on the performance of plants under different growing conditions, including drought and low nutrient stress. The company was founded in 1998 and is headquartered in Zwijnaarde, Blgium. | Miscellaneous Commercial Services | Director/Board Member Corporate Officer/Principal | |
| ABLYNX | Biotechnology | Director/Board Member Director/Board Member Chief Tech/Sci/R&D Officer Chief Tech/Sci/R&D Officer | |
| ZEALAND PHARMA A/S | Pharmaceuticals: Major | Director/Board Member Chairman | |
| University of Amsterdam | College/University | Undergraduate Degree Graduate Degree Graduate Degree Doctorate Degree | |
| Erasmus University Rotterdam | College/University | Undergraduate Degree Doctorate Degree Undergraduate Degree | |
| Delft University of Technology | College/University | Graduate Degree Graduate Degree | |
| University of Utrecht | College/University | Doctorate Degree Graduate Degree Doctorate Degree Doctorate Degree Graduate Degree Undergraduate Degree | |
MyCartis NV
 MyCartis NV BiotechnologyHealth Technology MyCartis NV develops technologies for healthcare personalization needs. It offers Evalution, a multiplex analysis platform to develop protein and nucleic-acid based clinical biomarkers. The company provides disruptive solutions in the fields of clinical and translational research for various applications in the detection of proteins and nucleic acids, such as sandwich immunoassays, antibody assays, genotyping assays, and mutation analysis assays to customers and partners. It offers products for various disease areas, including cell signalling, cardiovascular, oncology, and preeclampsia. The company was founded by Koen Kas in August 2004 and is headquartered in Ghent, Belgium. | Biotechnology | Director/Board Member Director/Board Member | |
Intrexon ActoBiotics NV
 Intrexon ActoBiotics NV BiotechnologyHealth Technology Intrexon ActoBiotics NV manufactures biopharmaceutical products. It focuses on the development and commercialization of a new generation of biological drugs. The company represents a novel concept for oral administration of therapeutic proteins, and is designed to be safer and more effective than injectable biopharmaceuticals. Intrexon Actobioticswas founded by Mark Vaeck, Emil Pot and Bernard Coulie in June 2006 and is headquartered in Zwijnaarde, Belgium. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
Aescap Venture Management BV
 Aescap Venture Management BV Investment ManagersFinance Aescap Venture Management BV is an independent venture capital investment firm based in Amsterdam. Aescap was founded in 2005 by Michiel de Haan and Dinko Valerio. Inspired by the name of the Greek god of healthcare, Aesculapiu, the firm's name is an acronym for 'Accelerating European Science Companies and Products.' The firm focuses on developing growth in European firms in the biomedical sector. | Investment Managers | Founder Private Equity Investor | |
Genzyme Europe BV
 Genzyme Europe BV Pharmaceuticals: MajorHealth Technology Part of Sanofi, Genzyme Europe BV is a Dutch company that develops and manufactures pharmaceutical and biotherapeutic products. The private company is based in Amsterdam, Netherlands. | Pharmaceuticals: Major | Corporate Officer/Principal Sales & Marketing | |
OxThera AB
 OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Generic | Director/Board Member Director/Board Member | |
AM-Pharma BV
 AM-Pharma BV BiotechnologyHealth Technology AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands. | Biotechnology | Director/Board Member Director/Board Member Corporate Officer/Principal | |
| Rotterdam University | College/University | Corporate Officer/Principal Graduate Degree | |
| ORPHAZYME A/S | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| SWEDISH ORPHAN BIOVITRUM AB | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| VERASTEM, INC. | Biotechnology | Director/Board Member Director/Board Member Sales & Marketing | |
CDC Entreprises Innovation
 CDC Entreprises Innovation Financial ConglomeratesFinance CDC Entreprises Innovation provides venture capital services. It invests in information technology, communication, life sciences and semi-conductor industries. The company is headquartered in France. | Financial Conglomerates | Chief Investment Officer Corporate Officer/Principal | |
Ovizio Imaging Systems SA
 Ovizio Imaging Systems SA Electronic ComponentsElectronic Technology Ovizio Imaging Systems SA develops and markets imaging systems and sensors. Its microscopes include iLine F, iLine M, iLine S and QMod. The company was founded by Catherine Yourassowsky, Frank Dubois, Philip Mathuis and Serge Jooris in December 2009 and is headquartered in Brussels, Belgium. | Electronic Components | Director/Board Member Director/Board Member | |
| GENSIGHT BIOLOGICS S.A. | Pharmaceuticals: Major | Director/Board Member Chief Tech/Sci/R&D Officer | |
Impatients NV
 Impatients NV Miscellaneous Commercial ServicesCommercial Services Impatients N.V. operates an online platform for drug innovations. It provides physicians and patients that are excluded from clinical trials access to drugs in development via early access programs. The company was founded by Ronald Brus, SJaak Vink, Govert J. Schouten, Witt Jan, Erdem Yavuz, and René Beukema in 2012 and is headquartered in Amsterdam, the United Kingdom. | Miscellaneous Commercial Services | Founder Director/Board Member Chairman | |
| PHARVARIS N.V. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Founder Founder | |
Amylon Therapeutics BV
 Amylon Therapeutics BV Pharmaceuticals: MajorHealth Technology Amylon Therapeutics BV is a biopharmaceutical company, which engages in the research and development of therapies for the central nervous system. It specializes in ribonucleic acid modulation technology to target rare genetic disorders. The company was founded by Thomas de Vlaam and is headquartered in Leiden, the Netherlands. | Pharmaceuticals: Major | Director/Board Member Founder | |
| Janssen Biotherapeutics | Corporate Officer/Principal Corporate Officer/Principal | ||
| X4 PHARMACEUTICALS, INC. | Biotechnology | Founder Director/Board Member | |
Vico Therapeutics BV
 Vico Therapeutics BV BiotechnologyHealth Technology Vico Therapeutics BV is a private biotech company based in Leiden, Netherlands that focuses on developing RNA modulating therapies for rare severe neurological disorders. The Dutch company's antisense oligonucleotide platform (AON) is directed towards different forms of spinocerebellar ataxia (SCA) and Huntington disease (HD), while its early discovery RNA editing platform is directed towards Rett syndrome. Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Gail Mandel, and Dr. Judith van Deutekom, who have strong academic reputations and vast industry experience. Micah Mackison has been the CEO of the company since 2022. | Biotechnology | Director/Board Member Director/Board Member Founder | |
Pharvaris GmbH
 Pharvaris GmbH Pharmaceuticals: MajorHealth Technology Pharvaris GmbH operates as a clinical-stage company. It specializes in medicinal chemistry, drug discovery and development and hereditary angioedema. The company was founded by Berndt A. E. Modig, Jochen Knolle, Anne Lesage and Hans G. C. P. Schikan in October 2015 and is headquartered in Zug, Switzerland. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Founder | |
Leyden Laboratories B.V.
 Leyden Laboratories B.V. Miscellaneous Commercial ServicesCommercial Services Leyden Laboratories B.V. is a biotechnology company based in Amsterdam, Netherlands. Leyden Labs aims to protect humanity from known and future viruses by targeting commonalities of viral families. The Dutch company has developed a portfolio of accessible intranasal product candidates that may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains of respiratory viruses, including ones in the influenza and coronavirus families. The company's energetic team of world-renowned biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses. Leyden Labs is backed with $200m by blue-chip investors Casdin Capital, GV (formerly Google Ventures), F-Prime Capital, Byers Capital/Brook Byers, SoftBank Investment Advisers, Invus, and Bluebird Ventures. The company was founded in June 2020 by Koenraad Wiedhaup, Jaap Goudsmit, Domenico Valerio, and Ronald H. P. Brus, with Koenraad Wiedhaup serving as the CEO since incorporation. | Miscellaneous Commercial Services | Founder Director/Board Member | |
EQT Life Sciences Group BV
 EQT Life Sciences Group BV Investment ManagersFinance EQT Life Sciences Group BV (EQT Life Sciences) is a venture capital firm, a subsidiary of EQT AB founded in 2022 after the acquisition of LSP by EQT. The firm is headquartered in Amsterdam, the Netherlands. | Investment Managers | Private Equity Investor Private Equity Investor |
Statistiques
Internationale
| Pays-Bas | 20 |
| Etats-Unis | 9 |
| Belgique | 9 |
| Royaume-Uni | 5 |
| Suisse | 4 |
Sectorielle
| Health Technology | 28 |
| Consumer Services | 10 |
| Commercial Services | 7 |
| Finance | 7 |
| Electronic Technology | 2 |
Opérationnelle
| Director/Board Member | 303 |
| Corporate Officer/Principal | 106 |
| Chairman | 60 |
| Independent Dir/Board Member | 54 |
| Chief Executive Officer | 42 |
Relations les plus connectées
| Insiders | |
|---|---|
| Antoine Papiernik | 48 |
| Henri A. Termeer | 42 |
| Martijn Kleijwegt | 33 |
| Rémi Droller | 29 |
| Luc Dochez | 26 |
| Alison Lawton | 24 |
| James Shannon | 22 |
| Jim van Heusden | 22 |
| Johannes G. C. P. Schikan | 22 |
| Stephen William Bunting | 22 |
| John Paul de Koning | 21 |
| Steven van Groningen | 18 |
| Theresa Heggie | 16 |
| Domenico Valerio | 15 |
| Jaap Tonckens | 15 |
- Bourse
- Insiders
- Gerard J. Platenburg
- Connexions Sociétés
